Abstract
Sarcopenia is a prognostic factor for cancer. Because creatinine is formed from creatine phosphate in muscle tissue, urinary creatinine excretion (UCE) serves as an index of muscle volume. However, as of yet, there are no studies assessing the clinical impact of UCE or weight- adjusted urinary creatinine excretion (WA-UCE) on allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We analyzed the association between pre-transplant WA-UCE and transplant outcomes among 164 adult patients with acute myeloid leukemia in complete remission who underwent their first allo-HSCT at our center. The patients were classified into a high (n = 106) and a low WA-UCE group (n = 58) for predicting overall survival (OS) based on the receiver operating characteristics curve. On multivariate analysis, low WA-UCE was associated with poor OS, progression-free survival and a high incidence of non-relapse mortality. WA-UCE has the potential to be an objective biomarker for predicting transplant outcomes, especially the incidence of infection-related death.
Acknowledgment
The authors thank the nursing staff at Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, for their excellent patient care.
Ethical approval
The protocol for this study was approved by the institutional ethics review board at Komagome Hospital, and informed consent for the retrospective analysis was obtained from all patients.
Authors contributions
AN, ND, TO, RK, HA, AW, YK, T Konishi, YY, RN, Y Noguchi, AM, JM, KI, TT, AI, Y Najima, HM, T Kobayashi, HS, and KO cared for the patients. ND and KO supervised the project. AN and ND analyzed data, created the figures, and wrote the manuscript.
Disclosure statement
No potential conflict of interest was reported by the author(s).